Welcome to our dedicated page for Avant Technologies news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on Avant Technologies stock.
Avant Technologies Inc. (OTCQB: AVAI) issues frequent updates about its joint ventures, licensing agreements, and development programs in biotechnology and healthcare-focused artificial intelligence. Its news releases describe how the company is building a partnership-driven model around genetically modified cell lines, encapsulation technologies, and AI platforms that target chronic and age-related diseases.
Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases.
Avant also reports on its collaboration with Ainnova Tech, Inc. through a joint venture that holds worldwide licensing rights to Ainnova’s Vision AI platform for early detection of diabetic retinopathy. News items describe regulatory interactions with the U.S. Food and Drug Administration, refinements to clinical trial protocols, and plans for patient recruitment in multiethnic populations at community and primary care sites.
Investors and observers following AVAI news can expect coverage of new joint venture agreements, updates on cell-based therapy programs, progress toward preclinical and clinical milestones, and developments in AI-based diagnostic initiatives. The company’s press releases also document corporate actions such as a proposed name change to Avaí Bio, Inc. and clarifications like the retraction of a previously announced but non-binding joint venture. This news feed allows readers to track how Avant’s partnership strategy evolves across its diabetes, longevity, and AI-driven healthcare efforts.
Avant Technologies (OTCQB: AVAI) announced a joint venture and license agreement with SGAustria to combine genetically modified insulin-producing cells with SGAustria's encapsulation technology.
The partners will form Insulinova, Inc. in the U.S. to facilitate and conduct clinical trials aimed at delivering long-term insulin production without immunosuppression using encapsulation like Cell-in-a-Box®.
The release highlights prior preclinical and clinical evidence for encapsulated beta cells and notes global diabetes prevalence estimates and forward-looking risks including development and financing.
Avant Technologies (OTCQB: AVAI) and Austrianova highlight a Mayo Clinic study linking low α-Klotho levels to arterial stiffness, vascular calcification and reduced survival in a 148‑patient cohort.
Avant and Austrianova’s joint venture, Klothonova, is developing an encapsulated, genetically modified cell therapy intended to sustainably restore circulating α-Klotho using Austrianova’s clinically validated Cell-in-a-Box® encapsulation platform.
The Mayo authors reported that low α-Klotho is independently associated with higher mortality and called for further research to clarify mechanisms and targeted treatments.
Avant Technologies (OTCQB: AVAI) and Singapore biotechnology company SGAustria announced a Joint Venture and License Agreement to develop a cell‑based diabetes therapy using stem cell differentiation and SGAustria’s encapsulation platform.
The partners will pursue a Research Collaboration Agreement (RCA), form a U.S. company named Insulinova, Inc. to facilitate clinical trials, and Avant will provide initial funding over the next eight months. SGAustria’s encapsulation technology is described as clinically proven and supported by over 50 peer‑reviewed publications and GMP manufacturing capabilities. The JV aims to enable a potential Phase 1 clinical trial in the United States or equivalent territory.
Avant Technologies (OTCQB: AVAI) and Austrianova launched joint venture Klothonova on Oct 21, 2025 to develop cell‑based therapies that overexpress the longevity protein Klotho.
R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and, when encapsulated in Austrianova’s Cell‑in‑Box, produced similar protein levels to non‑encapsulated cells. The JV is equally owned and will advance a GMP‑grade human cell clone toward preclinical and clinical studies; Austrianova is requalifying its ISO9001:2015 GMP isolator and preparing required documentation. The JV cites a cell therapy market projection of about $44 billion.
Avant Technologies (OTCQB: AVAI) announced a strategic shift towards partnership-driven biotechnology development through joint ventures and licensing agreements. The company is focusing on advancing treatments for chronic and age-related conditions including diabetes, Alzheimer's, heart disease, cancer, and kidney disease.
The company's strategy involves collaborating with biotech firms specializing in genetically modified cell lines and partnering with a global cell-encapsulation technology company. Their first joint venture with Ainnova Tech incorporates Vision AI for non-invasive disease detection, while their latest venture focuses on developing cell line therapy for Klotho protein production, crucial for aging and disease processes.
Avant Technologies (OTCQB: AVAI) has issued a retraction of its September 24, 2025 press release regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova. The company clarified that no binding agreement has been executed between the parties at this time.
The company acknowledged that the previous announcement contained statements issued in error and emphasized that any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones from the retracted release should not be relied upon. Avant Technologies expressed regret for any confusion caused and reaffirmed its commitment to providing accurate information to stakeholders.
Avant Technologies (OTCQB: AVAI) has formed a strategic Joint Venture with Art-Islets and Austrianova to develop innovative diabetes treatments using encapsulated stem cells. The collaboration combines Art-Islets' stem cell differentiation expertise with Austrianova's cell-encapsulation technology to create therapies for type 1 and insulin-dependent type 2 diabetes patients.
The partnership includes exclusive licensing agreements and plans for a potential U.S.-based entity to support clinical trials. Avant will provide initial funding over eight months to achieve the first three milestones, with additional funding planned to advance toward Phase 1 clinical trials. Art-Islets contributes its proprietary differentiation system for transforming ESCs into insulin-producing cells, while Austrianova brings its GMP-grade manufacturing expertise backed by over 50 peer-reviewed publications.
Avant Technologies (OTCQB: AVAI) and Austrianova have formed a joint venture called Klothonova, Inc. to develop cell-based therapies using encapsulated Klotho-producing cells. The 50/50 partnership combines Austrianova's proprietary cell-encapsulation technology and expertise with Avant's capital and resources.
The venture aims to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, and age-related conditions. Austrianova brings significant expertise backed by over 50 peer-reviewed publications and global partnerships, while focusing on the therapeutic properties of Klotho, an 'anti-aging' protein discovered in 1997 that plays a crucial role in modulating aging and various physiological functions.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced an enhanced patient recruitment strategy for their upcoming FDA clinical trial of the Vision AI platform, designed for early detection of diabetic retinopathy. The study will be conducted across 8-10 U.S. clinical sites, targeting approximately 1,000 multiethnic patients with diabetes.
The companies will collaborate with Fortrea, a renowned Contract Research Organization specializing in ophthalmology studies. The trial will focus on community clinics and primary care facilities rather than specialized centers to gather real-world data. This strategic approach aims to support the company's FDA 510(k) submission for Vision AI, with Ai-nova Acquisition Corp. (AAC) holding worldwide licensing rights for Ainnova's technology portfolio.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced updates to their clinical trial protocol following FDA feedback for their Vision AI platform. The revised protocol, focused on early detection of diabetic retinopathy, will be resubmitted to the FDA for review.
The companies are working through their Contract Research Organization, Fortrea, to advance the protocol that will enable initiation of a new clinical trial. The technology is being developed under Ai-nova Acquisition Corp. (AAC), a partnership between Avant and Ainnova, which holds worldwide licensing rights for Ainnova's technology portfolio.
FAQ
What is the current stock price of Avant Technologies (AVAI)?
What is the market cap of Avant Technologies (AVAI)?
